Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven

OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > Seeking alpha

<< Previous

Bullboard Posts

Next >>

Comment by mjh9413on Oct 07, 2016 9:14am

75 Views

Post# 25321610

RE:RE:RE:RE:RE:RE:RE:Seeking alpha

If long in ARZ that is a pretty cavalier attitude to the new drug purchase metrics, with a call to rely on Yosprala and think the buyer is smart enough. If one just takes the upfront purchse price and then takes gross to net margin 50% that is still a payback on net sales alone of at least 4 years out of the nine being mentioned. And you'll realise that is net margin, with lots of underlying expenses per unit sale still to be deucted from unit earnings. It is one thing to say it adds to EBITDA but the whole point of that ARZ is adding back the interest cost on the $175MM to earnings, which no one can tell me is NOT a cash cost.eom

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth